Plastic Surgeons Sound Alarm on Potential “Internal Bra” Mesh Complications

Plastic surgeons across the country are voicing concerns about the increasing use of surgical mesh in cosmetic breast procedures, particularly in techniques marketed as “internal bras.” These medical professionals warn that patients have reported experiencing complications allegedly caused by medical devices that were never approved for breast surgery applications, with many women facing painful recoveries and additional corrective operations.

What Are “Internal Bra” Procedures?

The internal bra technique represents a surgical approach where supportive mesh material is placed beneath breast tissue to create additional structure during augmentation, lift, or reconstruction procedures. Surgeons position mesh along the lower breast curve, creating a hammock-like support intended to maintain breast shape and position over time.

Unlike traditional breast surgeries that rely solely on internal suturing of natural tissues, mesh-based internal bras introduce foreign materials designed to function as permanent scaffolding. The procedure promises patients longer-lasting results by theoretically preventing tissue stretching and maintaining implant position.

Potential Complications of Internal Bra Mesh Procedures

These internal bra procedures have gained popularity through marketing that suggests the mesh creates a supportive sling similar to an external brassiere, but positioned inside the body. Manufacturers promote these materials as solutions for women concerned about post-surgical sagging or implant displacement.

However, board-certified plastic surgeons increasingly report that the theoretical benefits of breast mesh rarely materialize as promised, while the potential risks remain substantial and largely undisclosed to patients considering these medical procedures.

Mesh Products Repurposed for Use in Breast Surgery

The mesh materials commonly used in internal bra procedures were originally developed for entirely different medical applications. Products like GalaFLEX, Phasix, Strattice, and AlloDerm were primarily designed for hernia repair, abdominal wall reconstruction, and other soft-tissue reinforcement needs—not breast surgery.

Despite lacking specific FDA clearance for breast applications, these surgical mesh materials have been aggressively marketed to surgeons and patients as “internal support systems” for cosmetic and reconstructive breast procedures. 

What is Surgical Mesh?

Mesh products used in internal bra breast procedures fall into two main categories: synthetic meshes (like GalaFLEX and Phasix) made from slowly dissolving polymers, and biologic meshes (like Strattice and AlloDerm) created from processed animal or human tissue. Both types are being used in breast procedures despite limited evidence supporting their safety or effectiveness in this context.

The FDA has explicitly stated that no surgical mesh products have received approval specifically for breast surgery applications, making their use in these procedures technically “off-label”—a fact many patients report never being told before their operations.

Expert Surgeons Reject Internal Bra Marketing Claims

Double board-certified plastic surgeon Dr. Jeffrey Lind has become outspoken about the problems he observes with internal bra mesh. In widely shared social media content, he explains that patients frequently ask about the technique after seeing marketing materials suggesting it will provide superior, longer-lasting results.

“An internal bra to me is more of a marketing term,” Dr. Lind states. “I have never seen any definitive evidence, scientific, or even just seeing other surgeons’ work where the internal bra has provided any benefit whatsoever. In fact, it increases your cost of surgery and it can certainly increase your risk of surgery.”

Dr. Lind describes treating patients with serious complications following internal bra procedures performed by other surgeons. In one recent case, he encountered “a piece of mesh that did not incorporate into the tissue,” creating what he called “a complete disaster” requiring complex surgical correction.

Similarly, plastic surgeon Dr. Rami Sherif has raised concerns about mesh use in breast procedures. He notes in a YouTube video that while mesh is marketed as preventing “bottoming out” (where breast tissue droops below the implant), he finds “those breasts still do bottom out fairly often… and then you’ve just added a foreign device into the breast again.”

These surgeons represent a growing consensus that internal bra mesh introduces unnecessary potential risks without delivering the promised benefits, leading many to avoid the technique entirely in their practices.

FDA Mesh Warnings and Regulatory Concerns

In late 2023, the Food and Drug Administration issued an important safety communication emphasizing that no surgical mesh products have received FDA clearance or approval specifically for breast augmentation, reconstruction, or lifting procedures. This direct warning to practitioners highlighted the agency’s concerns about the growing off-label use of these materials.

The FDA also announced that GalaFLEX manufacturer Becton, Dickinson and Company had updated its product warnings and precautions to better reflect potential complications and concerns about off-label mesh use in breast surgeries. This regulatory action followed mounting reports of adverse events allegedly associated with mesh implantation in breast tissue.

Earlier FDA communications had already flagged certain acellular dermal matrix products (a type of biologic mesh) as having higher complication rates in breast reconstruction. The agency found that products like FlexHD and AlloMax were associated with increased risks of major complications, reoperation, infection, and implant loss compared to other options or procedures without mesh.

These regulatory actions underscore the fact that mesh products being marketed for internal bra techniques lack the rigorous testing and approval process that would normally be required for devices implanted in breast tissue.